Nancy Lurker - Jul 26, 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Jul 26, 2024
Transactions value $
$0
Form type
4
Date filed
7/26/2024, 04:47 PM
Previous filing
Jul 12, 2024
Next filing
Aug 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Gift $0 -1.56K -100% $0.00* 0 Jul 26, 2024 Common Stock 1.56K $12.90 Direct F1, F2
transaction EYPT Stock Option (Right to Buy) Gift $0 +1.56K +2.13% $0.00 74.8K Jul 26, 2024 Common Stock 1.56K $12.90 By Family Trust F1, F2, F3
transaction EYPT Stock Option (Right to Buy) Gift $0 -26.7K -46.15% $0.00 31.2K Jul 26, 2024 Common Stock 26.7K $13.13 Direct F1, F4
transaction EYPT Stock Option (Right to Buy) Gift $0 +26.7K +17.14% $0.00 183K Jul 26, 2024 Common Stock 26.7K $13.13 By Family Trust F1, F3, F4
transaction EYPT Stock Option (Right to Buy) Gift $0 -30K -24% $0.00 95K Jul 26, 2024 Common Stock 30K $10.13 Direct F1, F5
transaction EYPT Stock Option (Right to Buy) Gift $0 +30K +26.09% $0.00 145K Jul 26, 2024 Common Stock 30K $10.13 By Family Trust F1, F3, F5
transaction EYPT Stock Option (Right to Buy) Gift $0 -56.4K -16.67% $0.00 282K Jul 26, 2024 Common Stock 56.4K $3.26 Direct F1, F6
transaction EYPT Stock Option (Right to Buy) Gift $0 +56.4K +50% $0.00 169K Jul 26, 2024 Common Stock 56.4K $3.26 By Family Trust F1, F3, F6
transaction EYPT Stock Option (Right to Buy) Gift $0 -16.7K -25% $0.00 50K Jul 26, 2024 Common Stock 16.7K $9.11 Direct F1, F7
transaction EYPT Stock Option (Right to Buy) Gift $0 +16.7K $0.00 16.7K Jul 26, 2024 Common Stock 16.7K $9.11 By Family Trust F1, F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").
F2 The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full.
F3 These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4 The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.
F5 The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.
F6 The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027.
F7 The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027.